mRNA / LNP CDMOs with Clean FDA Inspection History
mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.
Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 14 NAI (no action), 26 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Germany (34), Denmark (29), United States (28), Italy (16), Spain (16).
Last updated 2026-09-24. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PC
|
90.1 | 100.0 | 4 insp · 14 GMP | 2025-12-16 · NAI | — | 366 programs |
| 2 |
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
|
86.7 | 100.0 | 0 insp · 35 GMP | None on file | — | |
| 3 |
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
|
83.1 | 99.3 | 5 insp · 17 GMP | 2025-11-14 · NAI | — | — |
| 4 |
RP
Keele, UK · Sodertalje, SE
|
82.9 | 100.0 | 0 insp · 3 GMP | None on file | — | — |
| 5 |
WK
Jena, DE · Amsterdam, NL · San Diego, CA
|
82.9 | 100.0 | 1 insp · 13 GMP | 2023-12-07 · VAI | — | — |
| 6 |
BNT
|
82.1 | 100.0 | 0 insp · 8 GMP | None on file | — | 28 programs |
| 7 |
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
|
81.9 | 98.8 | 2 insp · 2 GMP | 2025-04-28 · VAI | — | 22 programs |
| 8 |
KE
Seraing, BE
|
81.6 | 99.9 | 1 insp · 4 GMP | 2024-02-26 · VAI | — | — |
| 9 |
EK
Birmingham, AL · Vancouver, BC
|
81.5 | 99.8 | 2 insp · 2 GMP | 2025-09-11 · NAI | — | — |
| 10 |
ND
Milford, MA
|
80.3 | 100.0 | 4 insp · 0 GMP | 2026-08-12 · NAI | — | — |
| 11 |
AE
|
80.3 | 100.0 | 1 insp · 0 GMP | 2024-11-08 · NAI | — | — |
| 12 |
CRA
|
79.5 | 100.0 | 2 insp · 18 GMP | 2025-12-02 · NAI | — | — |
| 13 |
UM
Boston, MA
|
78.7 | 96.7 | 2 insp · 0 GMP | 2025-12-18 · VAI | — | — |
| 14 |
MR
|
77.9 | 100.0 | 4 insp · 4 GMP | 2025-11-21 · NAI | — | 10 programs |
| 15 |
CVC
|
75.3 | 100.0 | 0 insp · 7 GMP | None on file | — | 4 programs |
| 16 |
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
|
73.6 | 95.6 | 1 insp · 0 GMP | 2025-01-21 · VAI | Available | 9 programs |
| 17 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |